Please use this identifier to cite or link to this item:
10.1111/apt.14152
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kruis, W. | - |
dc.contributor.author | Kardalinos, V. | - |
dc.contributor.author | Eisenbach, T. | - |
dc.contributor.author | Lukas, M. | - |
dc.contributor.author | Vich, T. | - |
dc.contributor.author | Bunganic, I. | - |
dc.contributor.author | Pokrotnieks, Juris | - |
dc.contributor.author | Derova, J. | - |
dc.contributor.author | Kondrackiene, J. | - |
dc.contributor.author | Safadi, R. | - |
dc.contributor.author | Tuculanu, D. | - |
dc.contributor.author | Tulassay, Z. | - |
dc.contributor.author | Banai, J. | - |
dc.contributor.author | Curtin, A. | - |
dc.contributor.author | Dorofeyev, A. E. | - |
dc.contributor.author | Zakko, S. F. | - |
dc.contributor.author | Ferreira, N. | - |
dc.contributor.author | Björck, S. | - |
dc.contributor.author | Diez Alonso, M. M. | - |
dc.contributor.author | Mäkelä, J. | - |
dc.contributor.author | Talley, N. J. | - |
dc.contributor.author | Dilger, K. | - |
dc.contributor.author | Greinwald, R. | - |
dc.contributor.author | Mohrbacher, R. | - |
dc.contributor.author | Spiller, R. | - |
dc.date.accessioned | 2021-12-13T14:25:01Z | - |
dc.date.available | 2021-12-13T14:25:01Z | - |
dc.date.issued | 2017-08 | - |
dc.identifier.citation | Kruis , W , Kardalinos , V , Eisenbach , T , Lukas , M , Vich , T , Bunganic , I , Pokrotnieks , J , Derova , J , Kondrackiene , J , Safadi , R , Tuculanu , D , Tulassay , Z , Banai , J , Curtin , A , Dorofeyev , A E , Zakko , S F , Ferreira , N , Björck , S , Diez Alonso , M M , Mäkelä , J , Talley , N J , Dilger , K , Greinwald , R , Mohrbacher , R & Spiller , R 2017 , ' Randomised clinical trial : mesalazine versus placebo in the prevention of diverticulitis recurrence ' , Alimentary Pharmacology and Therapeutics , vol. 46 , no. 3 , pp. 282-291 . https://doi.org/10.1111/apt.14152 | - |
dc.identifier.issn | 0269-2813 | - |
dc.identifier.uri | https://dspace.rsu.lv/jspui/handle/123456789/7037 | - |
dc.description | Publisher Copyright: © 2017 The Authors. Alimentary Pharmacology and Therapeutics published by John Wiley & Sons Ltd | - |
dc.description.abstract | Background: Previous studies have reached conflicting conclusions regarding the efficacy of mesalazine in the prevention of recurrent diverticulitis. Aim: To investigate the efficacy and safety of mesalazine granules in the prevention of recurrence of diverticulitis after acute uncomplicated diverticulitis. Methods: Two phase 3, randomised, placebo-controlled, double-blind multicentre trials (SAG-37 and SAG-51) investigated mesalazine granules in patients with prior episodes (<6 months) of uncomplicated left-sided diverticulitis. Patients were randomised to receive either 3 g mesalazine once daily or placebo (SAG-37, n=345) or to receive either 1.5 g mesalazine once daily, 3 g once daily or placebo for 96 weeks (SAG-51, n=330). The primary endpoint was the proportion of recurrence-free patients during 48 weeks (SAG-37 and SAG-51) or 96 weeks (SAG-51) of treatment. Results: Mesalazine did not increase the proportion of recurrence-free patients over 48 or 96 weeks compared to placebo. In SAG-37, the proportion of recurrence-free patients during 48 weeks was 67.9% with mesalazine and 74.4% with placebo (P=.226). In SAG-51, the proportion of recurrence-free patients over 48 weeks was 46.0% with 1.5 g mesalazine, 52.0% with 3 g mesalazine and 58.0% with placebo (P=.860 for 3 g mesalazine vs placebo) and over 96 weeks 6.9%, 9.8% and 23.1% respectively (P=.980 for 3 g mesalazine vs placebo). Patients with only one diverticulitis episode in the year prior to study entry had a lower recurrence risk compared to >1 episode. Safety data revealed no new adverse events. Conclusion: Mesalazine was not superior to placebo in preventing recurrence of diverticulitis. | en |
dc.format.extent | 10 | - |
dc.format.extent | 465389 | - |
dc.language.iso | eng | - |
dc.relation.ispartof | Alimentary Pharmacology and Therapeutics | - |
dc.rights | info:eu-repo/semantics/openAccess | - |
dc.subject | 3.1 Basic medicine | - |
dc.subject | 3.2 Clinical medicine | - |
dc.subject | 1.1. Scientific article indexed in Web of Science and/or Scopus database | - |
dc.subject | Hepatology | - |
dc.subject | Gastroenterology | - |
dc.subject | Pharmacology (medical) | - |
dc.title | Randomised clinical trial : mesalazine versus placebo in the prevention of diverticulitis recurrence | en |
dc.type | /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article | - |
dc.identifier.doi | 10.1111/apt.14152 | - |
dc.identifier.url | http://www.scopus.com/inward/record.url?scp=85019564492&partnerID=8YFLogxK | - |
dc.description.status | Peer reviewed | - |
Appears in Collections: | Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure |
Files in This Item:
File | Size | Format | |
---|---|---|---|
Randomised_clinical_trial.pdf | 454.48 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.